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Abstract
Background: Semaphorin 3D (SEMA3D) plays important roles in the genesis and progress of many cancers. However,
the relationship between SEMA3D and colorectal cancer (CRC) remains unknown. The aim of this study was to
investigate whether SEMA3D can be used as a predictive marker for the diagnosis, metastasis, and prognosis of CRC by
assessing the expression of SEMA3D in the tissues and serum of CRC patients.
Methods: Real-time quantitative polymerase chain reaction (qPCR) was used to measure the expression of SEMA3D
mRNA in 100 CRC tissues and matched normal tissues. qPCR was also used to detect the expression of SEMA3D mRNA
in the CRC cell line RKO. RKO cells were transfected with SEMA3D small-interring RNA (siRNA) to interfere
with endogenous SEMA3D. The migratory ability of control and SEMA3D siRNA-transfected RKO cells was
determined by transwell assays. Enzyme-linked immunosorbent assay (ELISA) was utilized to detect the levels
of SEMA3D in the serum of 80 CRC patients and 100 normal healthy controls. The expression of SEMA3D in
215 CRC tissues was assessed using immunohistochemistry (IHC). Then, statistical analyses were adopted to
assess SEMA3D protein levels and clinical pathological characteristics.
Results: The mRNA expression of SEMA3D was significantly lower in CRC tissues than in paired normal tissues
(t = 5.027, P < 0.0001). Compared with normal healthy controls, the serum levels of SEMA3D were decreased
significantly in CRC patients (t = 3.656, P = 0.0003). The expression of SEMA3D protein was linked to lymph
node metastasis, and low expression led to lymph node metastasis (χ2 = 8.415, P = 0.004). The expression of
SEMA3D in CRC tissues was a favorable prognostic factor. Patients with a higher expression of SEMA3D experienced
longer survival (P = 0.002, log-rank [Mantel-Cox]; Kaplan-Meier). In addition, multivariate Cox’s proportional hazard
model revealed that SEMA3D is an independent prognostic marker (hazard ratio [HR] 1.818, 95% CI 1.063–3.110, P = 0.
029). Moreover, transwell assays showed that knocking down SEMA3D significantly increased RKO cell migration (t = 9.
268, P = 0.0008).
Conclusions: SEMA3D might function as a tumor suppressor during the formation and development of CRC. SEMA3D
might become a predictive marker for the diagnosis, metastasis, and prognosis of CRC and provide a novel target for
the prevention and treatment of CRC.
Keywords: SEMA3D, Colorectal cancer, Metastasis, Prognosis
* Correspondence: 11018140@zju.edu.cn
1Department of Pathology, The First Hospital of Jiaxing, Zhejiang, People’s
Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wang et al. World Journal of Surgical Oncology  (2017) 15:67 
DOI 10.1186/s12957-017-1128-1
Background
Colorectal cancer is a common malignant tumor occuring
in the digestive system and affects patients worldwide. The
International Agency for Research on Cancer (IARC) re-
ported that the worldwide new incidence rate of CRC was
the third and second highest cancer in males and females,
respectively, in 2012. However, CRC had the fourth and
third highest cancer-associated mortality rate worldwide in
males and females, respectively [1]. Recently, a Chinese
study revealed that 376,300 new cases of CRC and 191,000
fatalities were expected in 2015. In new cases, men and
women are accounted for fifth and fourth, respectively.
However, in mortality cases, both men and women are
accounted for fifth [2]. These authoritative data suggest
that CRC remains a major threat to human health. The de-
velopment of CRC is associated with complex interactions
between multiple genes and signaling pathways. However,
the mechanism behind CRC is still not fully understood.
In addition, tumor metastasis is an important contributor
to mortality in patients with CRC [3].
Recent research showed that SEMA3D which encodes a
member of the semaphorin III family of secreted signaling
proteins that are involved in axon guidance during neur-
onal development has a certain correlation with the devel-
opment of breast cancer, glioblastoma, pancreatic cancer,
thyroid cancer, and other tumors [4–8]. However, no link
between SEMA3D and CRC has been reported.
Our previous study used mRNA expression profile mi-
croarrays to show that the expression of SEMA3D was
significantly lower in CRC tissues than paired normal
tissues. Based on these results, the current study further
detected the mRNA and protein expression of SEMA3D
in CRC and paired normal tissues. Furthermore, the
serum levels of SEMA3D were measured in CRC pa-
tients and normal healthy controls. This study discussed
the role of SEMA3D in CRC, and the results may pro-
vide an experimental basis for further research into the
formation, development, prevention, diagnosis, and indi-
vidualized treatment of CRC.
Methods
Patients and specimens
CRC tissue specimens and paired normal mucosa for
mRNA detection were available from 100 CRC patients
(57 males and 43 females aged 34–86 years old, mean
age ± standard deviation (SD) 64.9 ± 11.4 years) who
underwent surgery between January and December 2015
at the First Hospital of Jiaxing. All the tissues were frozen
in liquid nitrogen immediately after surgery and then
stored at −80 °C until RNA extraction. A total of 215
formalin-fixed, paraffin-embedded CRC tissues (134 male
and 81 female patients aged 30–86 years, old, mean age ±
SD, 63.8 ± 11.0 years) from patients who were recruited
from the First Hospital of Jiaxing between January 2009
and December 2010 were used for immunohistochemis-
try. All these cases were followed-up, and clinicopatholog-
ical data were collected from medical records. In addition,
80 serum samples from CRC patients (42 males and 38 fe-
males aged 28–86 years; mean age ± SD, 65.1 ± 11.7 years)
and 100 serum samples from normal healthy control sub-
jects (52 males and 48 females aged 28–82 years, mean
age ± SD 61.6 ± 9.1 years) were obtained from the First
Hospital of Jiaxing between January and December 2015.
All the blood samples were centrifuged at 4 °C, aliquoted,
and stored at −80 °C until analysis by ELISA.
All samples from CRC patients were harvested before
radiotherapy or chemotherapy. All samples underwent
surgery, and all cases were diagnosed by two pathologists
independently.
Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from tissues using an RNeasy
Mini Kit (Qiagen, Catalog no. 74106) and cDNA was
synthesized using a PrimeScript® RT reagent kit (TaKaRa
Biotechnology, Dalian, China, Catalog no. RR037A). Q-
PCR was performed using SYBR® Premix Ex Taq
(TaKaRa; Catalog no. RR420A), and the relative gene ex-
pression levels were calculated using the 2−ΔΔCt method;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal control. The primer sequences
used were as follows: GAPDH forward, 5’-ACCACAG
TCCATGCCATCAC-3’and reverse, 5’-TCCACCACCC
TGTTGCTGTA-3’ (product length, 452 bp); SEMA3D




Formalin-fixed, paraffin-embedded sections of all 215
tissues were subjected to the EnVision method using
SEMA3D polyclonal antibodies (Novus, American, catalog
no. NBP1-85517, 1:50). Phosphate-buffered Saline (PBS)
was used as a negative control instead of the primary anti-
body. Sections were counterstained with hematoxylin.
Scoring method
As shown in Table 1, the total SEMA3D immunostain-
ing was scored as both the percentage of positive cells






0 0 No staining 0
<10% 1 + 1
10–50% 2 ++ 2
51–80% 3 +++ 3
>80% 4
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and the intensity of the cytoplasmic/cytomembrane
staining. All sections were reviewed by two experienced
pathologists independently. The SEMA3D staining score
of each section was calculated by multiplying the per-
centage and the intensity scores. A minimum measure-
ment score of 6 was defined as the overexpression of
SEMA3D, whereas a score < 6 was regarded as low
expression.
ELISA
The serum concentrations of SEMA3D were measured
using a sandwich enzyme-linked immunosorbent assay
kit according to the manufacturer’s instructions (Cusabio,
China, catalog no. CSB-EL020983HU).
Cell culture and siRNA transfection
The human CRC line RKO was purchased from the
American Type Culture Collection (Manassas, VA,
USA), was maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (HyClone,
Tauranga, New Zealand), and was grown at 37 °C in an
atmosphere containing 95% air and 5% CO2. siRNA spe-
cific for SEMA3D, and negative control were purchased
from Genepharma (Shanghai, China). All transfection
experiments were performed using Lipofectamine 2000
(Invitrogen), incubated for 48 h according to the manu-
facturer’s instructions.
Cell migration
To evaluate the migratory capacity of RKO cells, 24-well
plates equipped with cell culture inserts containing
8.0 μm pore size membranes (Costar Corp., Cambridge,
MA, USA) were used. Briefly, a total of 5 × 104 cells
were resuspended in 100 μl of serum-free medium and
placed in the upper chambers. The lower chamber was
filled with 10% PBS as the chemoattractant. At the end
of the experiments, cells on the upper surface of the fil-
ters were removed, and cells that had migrated to the
lower surface were fixed in 4% paraformaldehyde and
stained with 0.1% crystal violet. Then, the crystal violet
was quantified at 570 nm using spectrophotometry after
elution in 33% glacial acetic acid.
Statistical analysis
SPSS19.0 was utilized for all statistical analyses. Meas-
urement data are presented as means ± standard devia-
tions (x±s) and were compared using paired or unpaired
t tests as appropriate. Chi-square tests were used to
analyze the IHC data to identify correlations between
clinicopathological parameters and SEMA3D protein
levels. Overall survival was evaluated using log-rank
tests, and survival curves were plotted according to the
Kaplan-Meier method. Prognostic variables were ana-
lyzed using the multivariate Cox’s proportional hazard
model. All statistics were two-sided. P values <0.05 were
considered to indicate statistical significance.
Results
SEMA3D is differentially expressed between CRC and
paired normal tissues
Q-PCR was used to investigate whether the mRNA
expression of SEMA3D was different in CRC tissues and
paired normal tissues. As shown in Fig. 1, the expression
of SEMA3D mRNA was lower in 76 of 100 CRC tissues
compared with matched normal tissues. Statistical ana-
lysis revealed that the difference was statistically signifi-
cant (t = 5.027, P < 0.0001).
The serum levels of SEMA3D in CRC patients and normal
healthy controls
ELISA was used to measure the serum levels of
SEMA3D in 80 CRC patients and 100 normal healthy
controls. The results showed that the levels of SEMA3D
in CRC patients were 753.23 ± 395.28 pg/ml, compared
with 992.04 ± 464.97 pg/ml in normal healthy controls.
The serum levels of SEMA3D were reduced significantly
in CRC patients compared with controls (Fig. 2; t = 3.656,
P = 0.0003).
SEMA3D expression and clinicopathological parameters
A total of 215 CRC patients were included in the study.
The low and high expression of SEMA3D, as analyzed
using IHC method, is shown in Fig. 3. As shown in
Table 2, there was no statistically significant association
Fig. 1 Differential mRNA expression of SEMA3D in CRC and paired
normal tissues. SEMA3D mRNA expression was lower in CRC tissues
compared with paired normal tissues (P < 0.0001)
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between SEMA3D protein expression and age, gender,
site, size, general type, and differentiation. However,
lymph node metastasis was negatively correlated with
the expression of SEMA3D (χ2 = 8.415, P = 0.004); pa-
tients expressing only low levels of SEMA3D were prone
to lymph node metastasis.
SEMA3D expression and overall survival
All 215 patients were followed up. During the follow-up
period, 65 patients died and 150 patients survived. As
shown in Table 3, 45 and 20 deceased CRC patients
expressed low and high levels of SEMA3D, respectively.
Therefore, patients expressing low levels of SEMA3D
had a shorter overall survival, whereas high SEMA3D
expression indicated a longer survival (P = 0.002, log-
rank [Mantel-Cox]; Kaplan-Meier; Table 3 and Fig. 4).
High expression of SEMA3D in CRC tissues was a favor-
able prognostic factor. Cox’s multivariate proportional
hazard model revealed that SEMA3D is an independent
prognostic marker {hazard ratio [HR] 1.818, 95% CI,
1.063–3.110, P = 0.029) (Table 4).
Knocking down SEMA3D promotes the migration of RKO
cells
Finally, siRNA was used to knock down SEMA3D in
RKO cells. The results showed that the mRNA expression
of SEMA3D was significantly reduced by SEMA3D-
siRNA (Fig. 5a; t = 6.840, P = 0.0024). Compared with
control-siRNA, SEMA3D-siRNA significantly increased
the migration of RKO cells (Fig. 5b; t = 9.268, P = 0.0008).
Discussion
Semaphorins are important axon guidance factors that
play an important role in guiding the development of
Fig. 2 The serum levels of SEMA3D in CRC patients and normal
healthy controls. Compared with normal healthy controls, the serum
levels of SEMA3D were decreased significantly in CRC
patients (P = 0.0003)
Fig. 3 SEMA3D expression in human CRC tissues. a Low expression. b High expression. Original magnification ×400
Table 2 Relationship between SEMA3D expression and
clinicopathologic characteristic of CRC patients
Characteristics Number Expression of SEMA3D P
valueLow High
Age (years) 0.826
≤60 75 39 (52.0%) 36 (48.0%)
>60 140 75 (53.6%) 65 (46.4%)
Gender 0.767
Male 134 70 (52.2%) 4 (47.8%)
Female 81 44 (54.3%) 37 (45.7%)
Site 0.399
Colon 113 63 (55.8%) 50 (44.2%)
Rectum 102 51 (50%) 51 (50%)
Size (cm) 0.505
≤5 162 88 (54.3%) 74 (45.7%)
>5 53 26 (49.1%) 27 (50.9%)
General type 0.849
Ulcerated 93 50 (53.8%) 43 (46.2%)
Others 122 64 (52.5%) 58 (47.5%)
Differentiation 0.062
Well/moderate 169 84 (49.7%) 85 (50.3%)
Poor/undifferentiated 46 30 (65.2%) 16 (34.8%)
Lymph node metastasis 0.004
Negative 129 58 (45.0%) 71 (55.0%)
Positive 86 56 (65.1%) 30 (34.9%)
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the nervous system [9–12]. In addition to regulating the
growth of axons, semaphorins also play an important
role in regulating cell proliferation and migration, as well
as tumor occurrence, development, metastasis, and
angiogenesis [13–21].
SEMA3D, also named coll-2 or Sema-Z2, is a secreted
class-3 semaphorin. The semaphorin gene is located on
the 7q21.11 chromosome, and it has 17 exons and 16 in-
trons. The precursor SEMA3D peptide contains 777
amino acids, including a 36-amino acid signal peptide
and a 741-amino acid mature peptide. SEMA3D is se-
creted into the blood, where it plays an important role.
Thus, SEMA3D may be a potential serological marker
for cancer.
In recent years, SEMA3D has been studied in various
fields. Berndt et al. used zebrafish to demonstrate that
SEMA3D could promote neural crest cell growth and
proliferation via Wnt/TCF signaling [22]. However, a
Japanese research group suggested that SEMA3D may
damage neural development, which could be relevant in
schizophrenia [23]. Ton et al. found that SEMA3D could
regulate zebrafish fin regeneration via a Cx43-dependent
mechanism [24]. However, another study indicated that
the role of Cx43 in the regeneration of zebrafish fin
needed the coordinate between SEMA3D and Hapln1a
[25]. A recent study showed that SEMA3D could sup-
press the movement and migration of human umbilical
vein epithelial cells via the PI3K/Akt signaling pathway
[17]. In addition, two studies reported that SEMA3D
plays a crucial role during the development of the en-
teric nervous system, and that abnormal SEMA3D path-
way may lead to the occurrence of Hirschsprung’s
disease [26, 27].
Importantly, several recent studies have investigated
the role of SEMA3D in cancer. Kigel et al. demonstrated
that SEMA3D can inhibit the formation of breast cancer
[4]. Another study showed that the expression of
SEMA3D was lower in high-grade gliomas compared
with low-grade gliomas, which suggests that SEMA3D
functions as a tumor suppressor in gliomas [5]. By
implanting glioblastoma cells into the mouse cerebral
cortex, Sabag et al. demonstrated that SEMA3D could
inhibit blood vessel formation and could exert antitumor
effects, which suggests that SEMA3D may be used to
Table 3 Univariate survival analysis of CRC
Variable Numbers Cases of death P value
Age (years) 0.326
≤60 75 19 (25.3%)
>60 140 46 (32.9%)
Gender 0.706
Male 134 42 (31.3%)
Female 81 23 (28.4%)
Site 0.379
Colon 113 31 (27.4%)
Rectum 102 34 (33.3%)
Size(cm) 0.579
≤5 162 48 (29.6%)
>5 53 17 (32.1%)
General type 0.771
Ulcerated 93 27 (29.0%)
Others 122 38 (31.1%)
Differentiation 0.016
Well/moderate 169 46 (27.2%)
Poor/undifferentiated 46 19 (41.3%)
Lymph node metastasis <0.0001
Negative 129 21 (16.3%)
Positive 86 44 (51.2%)
Expression of SEMA3D 0.002
Low 114 45 (39.5%)
High 101 20 (19.8%)
Fig. 4 Kaplan-Meier curves in CRC patients according to SEMA3D
expression. Low SEMA3D expression in CRC patients was correlated
with a shorter overall survival compared with high SEMA3D
expression. Log-rank tests showed statistical significance (P = 0.002)
Table 4 Results of multivariate Cox’s proportional hazard model
Variable Relative risk (95% confidence interval) P
Age 0.755 (0.442–1.291) 0.305
Gender 1.150 (0.686–1.929) 0.596
Differentiation 0.677 (0.392–1.169) 0.161
Lymph node metastasis 0.277 (0.162–0.472) <0.0001
Expression of SEMA3D 1.818 (1.063–3.110) 0.029
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treat glioblastoma patients [6]. Another recent study
showed that the expression of SEMA3D was low in thy-
roid carcinoma, and concluded that it could be used as a
good diagnostic marker of cytologically indeterminate
thyroid cancers [8].
In pancreatic ductal adenocarcinoma (PDA), AnxA2
can promote the secretion and thereby increase the
levels of SEMA3D, and primary PDA patients that ex-
press high levels of SEMA3D have a wider range of me-
tastases than those who express lower levels of
SEMA3D [7]. SEMA3D is expected to become a novel
therapeutic target and prognostic indicator for meta-
static PDA. Intriguing, another study showed that hu-
man papilloma virus (HPV) can be integrated into
SEMA3D gene introns, which promotes the develop-
ment of cervical cancer [28]. These findings suggest that
SEMA3D may act as an oncogene or a suppressor gene
in different cancers.
Little research into the role of SEMA3D in CRC has
been reported. Our previous study used mRNA microar-
rays to show that the expression of SEMA3D is signifi-
cantly lower in CRC tissues than in paired normal
tissues. In the current study, we confirmed that
SEMA3D mRNA expression is higher in normal colorec-
tal mucosa than in CRC tissues. These results suggest
that SEMA3D may play a role in the formation and de-
velopment of CRC.
The results of IHC indicated that SEMA3D was pri-
marily localized in the cytoplasm or cytomembrane in
CRC. SEMA3D expression was inversely correlated with
lymph node metastasis, and patients with low SEMA3D
expression were prone to lymph node metastasis. Mean-
while, knocking down SEMA3D in RKO cells promoted
cell migration. These results indicate that SEMA3D may
inhibit CRC metastasis. Univariate survival analysis of
CRC showed that patients expressing high levels of
SEMA3D had longer survival than expressing low levels
of SEMA3D. This results were similar with the previous
study which showed that SEMA3D can prolong the sur-
vival of the mice in glioblastoma [6]. In addition, pa-
tients with lymph node metastasis had shorter overall
survival. Univariate analysis also revealed that SEMA3D
expression was inversely correlated with lymph node
metastasis. Moreover, a multivariate Cox’s proportional
hazard model revealed that SEMA3D is also an independ-
ent prognosis marker for CRC. The above data suggest
that SEMA3D functions as a protective factor in CRC.
The current study also investigated whether the serum
levels of SEMA3D could be a diagnostic marker in CRC.
The results suggested that SEMA3D serum levels were
significantly reduced in CRC patients compared with
normal healthy controls. This suggests that SEMA3D
serum levels could act as a diagnostic marker of CRC.
Taken together, the current study suggests that
SEMA3D may function as a tumor suppressor gene during
the formation and development of CRC. It might also be a
biomarker for the diagnosis, metastasis, and prognosis of
CRC. In addition, the current study provided theoretical
support of the mechanism for further colorectal cancer re-
search and provided a new direction for the prevention
and individualized treatment of CRC. Ultimately, this may
help improve the survival quality for CRC patients.
Conclusions
The current study indicated that SEMA3D might func-
tion as a tumor suppressor during the formation and
Fig. 5 Knocking down SEMA3D promoted RKO cell migration. a SEMA3D was detected in RKO cells that had been transfected with control or
SEMA3D siRNA using qPCR (P = 0.0024). b Migration assays were performed in RKO cells transfected with SEMA3D siRNA using transwell assays
(the right panel shows quantification P = 0.0008)
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development of CRC. SEMA3D levels were negatively
correlated with lymph node metastasis. Moreover,
SEMA3D was an independent prognostic marker in
CRC patients. SEMA3D is a potential predictive marker
for the diagnosis, metastasis, and prognosis of CRC, and
it represents a novel target for the prevention and treat-
ment of CRC.
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